Philips provides update on completed set of test results for first-generation DreamStation sleep therapy devices
December 21 2022 - 02:00AM
GlobeNewswire Inc.
Philips provides update on completed set of test results for
first-generation DreamStation sleep therapy devices
December 21, 2022
Amsterdam, the Netherlands – Royal Philips
(NYSE: PHG; AEX: PHIA) today provides an update on the
comprehensive test and research program of its subsidiary Philips
Respironics, following the voluntary recall notification/field
safety notice* to address potential health risks related to the
polyester-based polyurethane (PE-PUR) sound abatement foam in
specific CPAP, BiPAP and mechanical ventilator devices.
Following previous updates in December 2021 and June 2022,
additional test results and assessments have now been completed for
the first-generation DreamStation devices (approximately 68% of the
registered devices globally). These devices have not been exposed
to ozone cleaning in line with the instructions for use.
The test and research program has been conducted together with
five independent, certified testing laboratories, and the results
have been reviewed and assessed by third-party qualified experts
and Philips Respironics, as well as an external medical panel.
The full press release is available in the attached PDF and
available here.* Voluntary recall notification in the US/field
safety notice for the rest of the world.
For media questions, please
contact:
Steve KlinkPhilips Global Press OfficeTel.: +31 6
10888824E-mail: steve.klink@philips.com
Ben ZwirsPhilips Global Press OfficeTel.: +31 6 15213446E-mail:
ben.zwirs@philips.com
About Royal PhilipsRoyal Philips (NYSE: PHG,
AEX: PHIA) is a leading health technology company focused on
improving people's health and well-being, and enabling better
outcomes across the health continuum – from healthy living and
prevention, to diagnosis, treatment and home care. Philips
leverages advanced technology and deep clinical and consumer
insights to deliver integrated solutions. Headquartered in the
Netherlands, the company is a leader in diagnostic imaging,
image-guided therapy, patient monitoring and health informatics, as
well as in consumer health and home care. Philips generated 2021
sales of EUR 17.2 billion and employs approximately 79,000
employees with sales and services in more than 100 countries. News
about Philips can be found at www.philips.com/newscenter.
Forward-looking statements This statement
contains certain forward-looking statements with respect to the
financial condition, results of operations and business of Philips
and certain of the plans and objectives of Philips with respect to
these items. Examples of forward-looking statements include
statements made about the strategy, estimates of sales growth,
future EBITA, future developments in Philips’ organic business and
the completion of acquisitions and divestments. By their nature,
these statements involve risk and uncertainty because they relate
to future events and circumstances and there are many factors that
could cause actual results and developments to differ materially
from those expressed or implied by these statements.
- Philips provides update on completed set of test results for
first-generation DreamStation sleep therapy devices
Koninklijke Philips NV (EU:PHIA)
Historical Stock Chart
From Feb 2023 to Mar 2023
Koninklijke Philips NV (EU:PHIA)
Historical Stock Chart
From Mar 2022 to Mar 2023
